NPS Pharma to Present at Leerink Partners Rare Disease Roundtable
September 24 2014 - 3:10PM
Business Wire
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) will present at the
Leerink Partners Rare Disease Roundtable in New York on Wednesday,
October 1, 2014 at 2:45 p.m. ET. The presentation will be available
as a live webcast with a replay available approximately three hours
after the presentation has concluded. Interested parties may access
the webcast from the investors’ events page on the NPS Pharma
website at http://ir.npsp.com/events.cfm.
About NPS Pharma
NPS Pharma is a global biopharmaceutical company pioneering and
delivering therapies that transform the lives of patients with rare
diseases. The company’s current therapeutic areas of focus are
gastrointestinal disease and endocrine disorders. These include
Short Bowel Syndrome, a potentially fatal gastrointestinal disorder
in which patients may have to rely on parenteral nutrition for
their survival; Hypoparathyroidism, a complex endocrine disorder in
which the parathyroid glands are either absent or damaged, and the
body produces insufficient or no parathyroid hormone; and Autosomal
Dominant Hypocalcemia, an ultra-rare, genetic disorder of calcium
homeostasis caused by mutations of the calcium-sensing receptor
gene. NPS Pharma continues to seek in-licensing opportunities to
develop new therapies for a broad range of rare diseases, and
complements its proprietary programs with a royalty-based portfolio
of products and product candidates that includes agreements with
Amgen, GlaxoSmithKline, Janssen Pharmaceuticals, and Kyowa Hakko
Kirin. NPS Pharma has operations in the U.S., Canada, Europe, Latin
America and Japan. Learn more at: www.npsp.com.
“NPS Pharma” and “NPS Pharmaceuticals” are the company's
trademarks.
NPS PharmaGail Brophy, 908-450-5335gbrophy@npsp.com
Nps (NASDAQ:NPSP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nps (NASDAQ:NPSP)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about (MM) (NASDAQ): 0 recent articles
More Nps Pharmaceuticals, Inc. (MM) News Articles